Difficulties in the diagnostics of transthyretin amyloidosis with polyneuropathy: a clinical case description

Abstract

BACKGROUND: In clinical practice, diagnosing of systemic transthyretin amyloidosis (ATTR-amyloidosis) with the impairment of the nervous and cardiovascular systems became possible due to the accessibility of genetic diagnostics and due to the growth of knowledge on this disease. CLINICAL CASE DESCRIPTION: A clinical case is presented of transthyretin amyloidosis, manifesting as polyneuropathy with significant neuropathic pain syndrome, with the development of severe vegetative insufficiency and with the impairment of the cardiovascular system in a 63 years old male. This clinical pattern, developing for 3 years, was associated with multiple encounters of the patient to various specialists — rheumatology physicians, neurosurgery specialists, endocrinologists, neurologists, internists, including surgical interventions in the spinal cord, carotid artery and cardiac vessels. The disease has lead to the development of severe cachexia and incapacitation of the patient. CONCLUSION: Taking into consideration that ATTR-amyloidosis manifests with the clinical signs of lesions in various organs and systems, and this is interpreted by the specialists within the framework of their specific field apart from the general etiology of the disease. The patient gets prescribed with multiple examinations and symptomatic medications, which causes a delay in the diagnostics and in setting the correct diagnosis. This clinical case describes the classical form of transthyretin amyloidosis, which, upon timely diagnostics, has its pathogenetic therapy.

Keywords

transthyretin amyloidosis / polyneuropathy / vegetative dysfunction / orthostatic hypotension / clinical case

References

[1] Адян Т.А., Поляков А.В. Наследственный транстиретиновый амилоидоз // Нервно-мышечные болезни. 2019. Т. 9, № 4. С. 12–25. [Adyan TA, Polyakov AV. Hereditary transthyretin amyloidosis. Neuromuscular diseases. 2019;9(4):12–25]. doi: 10.17650/2222-8721-2019-9-4-12-25 EDN: NRNWQQ

[2] Никитин С.С., Бардаков С.Н., Супонева Н.А., и др. Фенотипическая гетерогенность и особенности диагностики транстиретинового амилоидоза с полинейропатией // Нервно-мышечные болезни. 2021. Т. 11, № 3. С. 12–36. [Nikitin SS, Bardakov SN, Suponeva NA, et al. Phenotypic heterogeneity and diagnostic features of transthyretin amyloidosis with polyneuropathy. Neuromuscular diseases. 2021;11(3):12–36]. doi: 10.17650/2222-8721-2021-11-3-12-36 EDN: MSVKOX

[3] Копишинская С.В. Транстиретиновая семейная амилоидная полинейропатия // Журнал неврологии и психиатрии им. С.С. Корсакова. 2018. Т. 118, № 10. С. 82-89. [Kopishinskaia SV. Transthyretin familial amyloid polyneuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(10):82-89]. doi: 10.17116/jnevro201811810182 EDN: YOYQUP

[4] Sekijima Y. Recent progress in the understanding and treatment of transthyretin amyloidosis. J Clin Pharm Ther. 2014;39(3):225–233. doi: 10.1111/jcpt.12145

[5] Vieira M, Saraiva MJ. Transthyretin: A multifaceted protein. Biomol Concepts. 2014;5(1):45–54. doi: 10.1515/bmc-2013-0038

[6] Гудкова А.Я., Шавловский М.М., Соловьев К.В., и др. Системный транстиретиновый амилоидоз. Санкт-Петербург, 2016. 39 с. [Gudkova AY, Shavlovsky MM, Soloviev KV, et al. Systemic transthyretin amyloidosis. Saint Petersburg; 2016. 39 р. (In Russ.)]

[7] Adams D, Suhr OB, Hund E, et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016;29(1):S14–26. doi: 10.1097/WCO.0000000000000289

[8] Coelho T, Ines M, Conceicao I, et al. Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy. Neurology. 2018;91(21):e1999–e2009. doi: 10.1212/WNL.0000000000006543

[9] Gundapaneni BK, Sultan MB, Keohane DJ, Schwartz JH. Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy. Eur J Neurol. 2018;25(3):464–468. doi: 10.1111/ene.13510

[10] Schmidt HH, Waddington-Cruz M, Botteman MF, et al. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2018;57(5):829–837. doi: 10.1002/mus.26034

[11] Waddington Cruz M, Benson MD. A review of tafamidis for the treatment of transthyretin-related amyloidosis. Neuro Ther. 2015;4(2):61–79. doi: 10.1007/s40120-015-0031-3

[12] Waddington Cruz M, Amass L, Keohane D, et al. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid. 2016;23(3):178–183. doi: 10.1080/13506129.2016.1207163

RIGHTS & PERMISSIONS

Eco-Vector